Zobrazeno 1 - 10
of 421
pro vyhledávání: '"Cheney R"'
Autor:
Kerr, K.M. *, Dafni, U., Schulze, K., Thunnissen, E., Bubendorf, L., Hager, H., Finn, S., Biernat, W., Vliegen, L., Losa, J.H., Marchetti, A., Cheney, R., Warth, A., Speel, E.-J., Blackhall, F., Monkhorst, K., Jantus Lewintre, E., Tischler, V., Clark, C., Bertran-Alamillo, J., Meldgaard, P., Gately, K., Wrona, A., Vandenberghe, P., Felip, E., De Luca, G., Savic, S., Muley, T., Smit, E.F., Dingemans, A.-M.C., Priest, L., Baas, P., Camps, C., Weder, W., Polydoropoulou, V., Geiger, T.R., Kammler, R., Sumiyoshi, T., Molina, M.A., Shames, D.S., Stahel, R.A., Peters, S.
Publikováno v:
In Annals of Oncology January 2018 29(1):200-208
Autor:
SPENCER, J.1, CHENEY, R. L.1
Publikováno v:
International Journal of Production Research. Oct72, Vol. 10 Issue 4, p333-349. 17p. 5 Diagrams, 4 Charts, 1 Graph.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Introduction: KRAS mutations, the most frequent gain-of-function alterations in NSCLC, are currently emerging as potential predictive therapeutic targets. The role of KRAS-G12C (Kr_G12C) is of special interest after the recent discovery and preclinic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::be04539351624bcbfc6141120db14359
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3102356
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3102356
PD-L1, as assessed by immunohistochemistry, is a predictive biomarker for immuno-oncology treatment in lung cancer. Different scoring methods have been used to assess its status, resulting in a wide range of positivity rates. We use the European Thor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::f02fc25a4341656e52192cf3c9795bab
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3121206
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3121206
Autor:
Thunnissen E, Kerr K, Dafni U, Bubendorf L, Finn S, Soltermann A, Biernat W, Cheney R, Verbeken E, Warth A, Marchetti A, Speel E, Pokharel S, Quinn A, Monkhorst K, Navarro A, Madsen L, Tsourti Z, Geiger T, Kammler R, Peters S, Stahel R, European Thoracic Oncology Platform Lungscape Consortium
Publikováno v:
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
r-FIHGUV. Repositorio Institucional de Producción Científica de la Fundación de Investigación del Hospital General de Valencia
instname
r-FIHGUV. Repositorio Institucional de Producción Científica de la Fundación de Investigación del Hospital General de Valencia
instname
PD-L1, as assessed by immunohistochemistry, is a predictive biomarker for immuno-oncology treatment in lung cancer. Different scoring methods have been used to assess its status, resulting in a wide range of positivity rates. We use the European Thor
Introduction: The PD-L1 biomarker is an important factor in selecting patients with non-small cell lung cancer for immunotherapy. While several reports suggest that PD-L1 positivity is linked to a poor prognosis, others suggest that PD-L1 positive st
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::71b2069f80b9ec81271a3f5b05e09b18
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3077599
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3077599
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Background: Reported prevalence of driver gene mutations in non-small-cell lung cancer (NSCLC) is highly variable and clinical correlations are emerging. Using NSCLC biomaterial and clinical data from the European Thoracic Oncology Platform Lungscape
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::bed13b33b5322282a98b137fda21a702
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3107977
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3107977
Introduction: The reported prevalence of ALK receptor tyrosine kinase gene (ALK) rearrangement in NSCLC ranges from 2% to 7%. The primary standard diagnostic method is fluorescence in situ hybridization (FISH). Recently, immunohistochemistry (IHC) ha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::2a7593a2d3ab8d4d6ce01fff07c107d0
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3107651
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3107651